Supernus Pharmaceuticals, Inc. Contact Us
Site Map
Privacy
Legal
Home
About Us
Supernus Pipeline
Epilepsy
Parkinson's Disease
Conduct Disorder
Depression
Anxiety
Patent List
Investors
Partnering
Career Center

Print This
Email This

Search
Anxiety

Anxiety involves a complex combination of emotions that include fear, apprehension, and worry. It is often accompanied by physical sensations such as heart palpitations, nausea, chest pain, shortness of breath, or tension headache.

Anxiety Disorders affect about 40 million American adults age 18 years and older (about 18%) in a given year. Unlike the relatively mild, brief anxiety caused by a stressful event (such as speaking in public), anxiety disorders last at least 6 months and can get worse if they are not treated.

Each anxiety disorder has different symptoms, but all the symptoms cluster around excessive, irrational fear and dread.

Anxiety Programs

SPN805 and SPN808:

  • Supernus is pursuing a novel PK profile and dosing schedule to provide improved therapy.
  • Single dose human PK study has been completed.